Jimcihii, maamulaha dawada Midowga Yurub ayaa soo saaray 'talo' taageeraya isticmaalka degdegga ah ee dawada cusub ee ka hortagga coronavirus ee ay soo saartay shirkad dawooyin caalami ah oo Mareykan ah. Merck iyada oo lala kaashanayo Ridgeback Biotherapeutics, in kasta oo aanay wali oggolaan masuuliyiinta Maraykanku.

The Wakaaladda Daawooyinka Yurub (EMA) ayaa ku taliyay isticmaalka degdega ah MerckKiniinka loogu talagalay daaweynta bukaannada COVID-19 ee caafimaad ahaan u nugul iyadoo kiisaska cusub ee coronavirus ay ku soo badanayaan qaaradda Yurub.

Hadal qoraal ah, EMA ayaa sheegay in dawada loo yaqaan Lagevrio - oo sidoo kale loo yaqaan molnupiravir ama MK 4482 - "waxaa loo isticmaali karaa in lagu daweeyo dadka waaweyn ee qaba COVID-19 kuwaas oo aan u baahnayn ogsijiin dheeri ah oo halis dheeraad ah ugu jira inay qaadaan COVID-19 daran."

Maamulaha EU wuxuu yiri daawaynta waa in la bixiyaa sida ugu dhaqsaha badan ka dib marka COVID-19 la ogaado iyo shan maalmood gudahooda ee bilowga calaamadaha. Daawada waa in la qaataa laba jeer maalintii muddo shan maalmood ah.

The EMA liiska dhibaatooyinka ka iman kara kaniiniga, oo ay ku jiraan shuban fudud ama dhexdhexaad ah, lallabo, dawakhaad iyo madax-xanuun. Daaweynta laguma talin haweenka uurka leh.

Xakamaynta ayaa ku dhawaaqday horaantii jimcaha inay bilowday dib u eegista daawada Pfizer ee Paxlovid ee COVID-19 iyadoo ujeedadu la mid tahay "in la taageero mas'uuliyiinta qaranka" kuwaas oo laga yaabo inay go'aan ka gaaraan isticmaalkeeda hore ka hor fasaxa suuq-geynta iyadoo loo eegayo kiisaska sii kordhaya iyo dhimashada Yurub.

Maanta, Austria waxay ku dhawaaqday inay geli doonto xiritaan cusub oo dalka oo dhan laga bilaabo Isniinta ayna ka dhigi doonto tallaal qasab ah, halka mas'uuliyiinta caafimaadka Jarmalka ay sheegeen in waddanku isu beddelay "hal dillaac weyn."

Labada Pfizer iyo Merck waxay ka codsadeen oggolaanshaha dawooyinkooda coronavirus Maamulka Cuntada iyo Dawooyinka ee Mareykanka, laakiin ma cadda goorta la ogolaan karo.

MAXAA LAGU QAADAYAA MAQAALKAN:

The regulator announced earlier on Friday that it had begun reviewing Pfizer's medicine Paxlovid for COVID-19 with the same goal “to support national authorities” who may decide on its early use prior to marketing authorization in light of rising cases and deaths in Europe.
In a statement, EMA said the drug called Lagevrio – also known as molnupiravir or MK 4482 – “can be used to treat adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of developing severe COVID-19.
The European Medicines Agency (EMA) has recommended the emergency use of Merck's pill for the treatment for clinically vulnerable COVID-19 patients as new coronavirus cases spike across the European continent.